Skip to content

CHIPS (Control of Hypertension in Pregnancy Study): A Pilot Trial

Control of Hypertension in Pregnancy Study: A Pilot Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00187395
Enrollment
132
Registered
2005-09-16
Start date
2003-04-30
Completion date
2005-12-31
Last updated
2009-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient Hypertension, Pregnancy

Keywords

hypertension, blood pressure, pregnancy

Brief summary

Prior to undertaking CHIPS which will be a large and difficult trial, we believe we need to first determine whether clinicians will comply with the interventions of 'less tight' and 'tight' control of dBP, and whether the interventions will result in differences in mean dBP between groups. A pilot will also allow us to confirm the ability of centres to identify eligible women and the willingness of women to join CHIPS.

Detailed description

To determine whether 'less tight' control of mild-moderate non-proteinuric maternal hypertension, aiming for a diastolic blood pressure (dBP) of 100mmHg, can decrease the risks of adverse perinatal outcome without increasing maternal risk compared with 'tight' control, aiming for a dBP of 85mmHg.

Interventions

PROCEDURERandomized to either a 'less tight' group or a 'tight' group

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
No

Inclusion criteria

* dBP 90-109mmHg due to pre-existing or gestational hypertension; live fetus(es); and 20-33+6 weeks.

Exclusion criteria

* dBP consistently \< 85mmHg by home BP monitoring; severe systolic hypertension; proteinuria; contraindication to either arm of the trial or to prolongation of pregnancy; or known lethal/major fetal anomaly.

Design outcomes

Primary

MeasureTime frame
Mean dBP at 28, 32 and 36 weeks gestation

Secondary

MeasureTime frame
Clinician compliance with treatment protocols; women's satisfaction with care.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026